Materias dentro de su búsqueda.
Mostrando 261 - 280 Resultados de 69,886 Para Buscar '"ONCE"', tiempo de consulta: 2.98s Limitar resultados
  1. 261
    “…ReSTORE (NCT03667690) is a global, double-blind, double-dummy, 1:1 randomized, controlled, Phase 3 non-inferiority trial that evaluated the efficacy and safety of rezafungin once weekly (QWk) versus caspofungin once daily (QD) in patients with candidaemia and/or IC. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
  2. 262
    “…METHODS: A comprehensive and systematic search was carried out on reputable databases including PubMed, the Cochrane Library, and Elsevier’s ScienceDirect to identify relevant studies that compared the efficacy of once-weekly Semaglutide with once-daily Sitagliptin in individuals diagnosed with type 2 diabetes mellitus. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparative efficacy and safety profile of once-weekly Semaglutide versus once-daily Sitagliptin as an add-on to metformin in patients with type 2 diabetes: a systematic review and meta-analysis
  3. 263
    “…As it is important to establish the long-term safety and efficacy of treatments for a chronic disease such as OA, the present study compared the effects of lumiracoxib at doses of 100 mg once daily (o.d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis
  4. 264
    “…This article reviewed the efficacy of liraglutide once daily in achieving clinical guidelines-recommended glycated hemoglobin A1c levels in patients with T2D compared with exenatide twice daily, or sitagliptin once daily, based on published literature, with an aim to elucidate the preferred choice of incretin-related therapy in treating uncontrolled T2D.…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
  5. 265
    “…AIMS: To investigate, in a 26‐week, open‐label, randomized, treat‐to‐target trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) once daily vs insulin glargine (IGlar) once daily in adults with Type 2 diabetes, inadequately controlled on basal insulin. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of once‐daily insulin degludec/insulin aspart compared with once‐daily insulin glargine in participants with Type 2 diabetes: a randomized, treat‐to‐target study
  6. 266
    “…INTRODUCTION: This trial was conducted to compare the efficacy of low dose once‐a‐week cisplatin and once‐every‐3‐weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
  7. 267
    “…The objective of this phase 3 study (NCT03874013) was to compare the efficacy and safety of once-weekly somatrogon with once-daily Genotropin in Japanese children with GHD. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study
  8. 268
    por Pisarskaya, L.
    Publicado 1974
    Libro
    Les émaux russes, XIe-XIXe s. [i.e.] once y diecinueve : colléctions des Musées: Musées du Kremlin de Moscou, Musée Historigue d'Etat, L'Ermitage
  9. 269
    por Pérez Olvera, Carmen de la Paz
    Publicado 1980
    Libro
    Estudio anatómico de la madera de once especies de angiospermas /
  10. 270
    por Vitug, Jason
    Publicado 2016
    Enlace del recurso
    You only live once: the roadmap to financial wellness and a purposeful life
  11. 271
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Once in a Blue Moon: Iatrogenic Coronary Dissection in Anomalous Coronary Artery
  12. 272
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Once upon a Testis: The Tale of Cyclic Nucleotide Phosphodiesterase in Testicular Cancers
  13. 273
    “…Twice-a-day (TAD) milking during the whole lactation is practiced in about 55% of New Zealand herds and once-a-day (OAD) milking during the whole lactation in about 10% of herds. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    A review of once-a-day milking in dairy cow grazing systems
  14. 274
    “…Following the superior clinical outcome with the once-daily GLP-1 RA liraglutide (Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results [LEADER]), this review examines and summarizes the effects of once-weekly GLP-1 RAs, including exenatide extended release (ER), dulaglutide, and semaglutide, on reducing cardiovascular events in patients with T2DM. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cardiovascular Outcomes with Once-Weekly GLP-1 RAs: Clinical and Economic Implications
  15. 275
    “…Moreover, the value of a once-weekly (QW) administration of oral medications for T2DM compared to once, twice, or thrice daily (QD, BID, TID) regimens is unclear. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patient Preference for Once-Weekly Dosing in Type 2 Diabetes Mellitus in Japan
  16. 276
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Mechanisms and predictors of menses resumption once normal weight is reached in anorexia nervosa
  17. 277
    “…This post-hoc analysis evaluated the efficacy and tolerability of duloxetine in the subset of 159 (75 duloxetine and 84 placebo) patients with milder MDD (baseline HAMD(17) total score ≥15 and ≤18) who were treated once daily with duloxetine 60 mg or placebo in two identical, 9-week, randomised, double-blind trials. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Texto
    Duloxetine 60 mg once daily in the treatment of milder major depressive disorder
  18. 278
    Enlace del recurso
    Enlace del recurso
    Texto
    “One pill, once daily”: what clinicians need to know about Atripla™
  19. 279
    “…These studies are reviewed to demonstrate the efficacy and safety of two different monthly regimens of risedronate in the treatment of postmenopausal osteoporosis: 75 mg on 2 consecutive days a month and 150 mg once a month. Data for oral risedronate 150 mg once a month are limited to 1 year’s treatment duration. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis
  20. 280
    por Flamholc, Leo, Gisslén, Magnus
    Publicado 2008
    “…Fosamprenavir is a protease inhibitor with a rather long half-life which makes it a candidate for once-daily use. Once-daily dosage of ritonavir-boosted fosamprenavir is approved in the US, but not in Europe, for treatment in patients without prior antiretroviral treatment. …”
    Enlace del recurso
    Enlace del recurso
    Texto
    Once-daily fosamprenavir with ritonavir in the treatment of HIV infection in therapy-naïve patients
Herramientas de búsqueda: RSS